ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Abstract Number: 0703

Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
Abstract Number: 0145

Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases
Abstract Number: 1842

Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
Abstract Number: 0389

Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study
Abstract Number: 1880

Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
Abstract Number: 2052

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
Abstract Number: 2095

Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry
Abstract Number: 1242

Validation of a Novel Ultrasound Scoring System for the Evaluation of Pediatric Knee Arthritis
Abstract Number: 1562

Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification
Abstract Number: 1199

Validation of New Medication User Definitions in Single-Specialty EHR Data
Abstract Number: 2170

Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1198

Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus
Abstract Number: 1362

Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
Abstract Number: 0453

Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
Abstract Number: 1022

Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
Abstract Number: 0595

Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
Abstract Number: 0396

Validity of Syndesmophyte Detection on Low Dose Computed Tomography in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 0155

Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Abstract Number: 1517

Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain
Abstract Number: 0962

Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Abstract Number: 1825

Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Abstract Number: 1608

Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Abstract Number: 1574

Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Abstract Number: 1251

Venous Halo Sign Detected with Superb Microvascular Imaging in Behçet Syndrome
Abstract Number: 0557

VEXAS Syndrome Is Characterized by Blood and Tissues Inflammasome Pathway Activation and Monocyte Dysregulation
Abstract Number: 1029

Virtual Assessment in Axial Spondyloarthritis: Validation of Video Observation of Spinal Metrology
Abstract Number: 0749

Virtual Care in Rheumatology Ambulatory Clinics During the COVID-19 Pandemic: Patient/Family and Healthcare Provider Perspectives and Experiences
Abstract Number: 0205

Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
Abstract Number: 1059

Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
Abstract Number: 0924

Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
Abstract Number: 1200

Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
Abstract Number: 1653

Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
Abstract Number: 0357

Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Abstract Number: 1573

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].